Abstract | AIM: The aim of this study was to evaluate the efficacy of 51Cr-EDTA clearance to tailor the carboplatin dose in two different therapeutic regimens of advanced epithelial ovarian cancer. MATERIALS AND METHODS: 14 patients entered the study, eight treated by carboplatin (C) alone and six by C and paclitaxel (P). The dose of C was calculated from the Calvert formula [DOSE(mg) = desired AUC x (GFR + 25)] based on the Glomerular filtration rate (GFR) figure; in our protocol desired Area under the curve (AUC) figure was 5 mg/ml x min. The method used to calculate the GFR requires only 4 blood samples taken in the late part of the disappearance plasmatic curve and conjugates accuracy to an acceptable clinical compliance. RESULTS: In only 5 courses a significant hematological toxicity (HT) was present (4 courses grade 2, 1 course grade 3); it was necessary to delay only 2 courses; no treatment was discontinued because of HT. CONCLUSION: We concluded that there is no summation toxicity of C and P if administered simultaneously and that the assessment of GFR by 51Cr-EDTA clearance is an optimal tool to predict an acceptable toxicity.
|
Authors | G Martino, V Frusciante, A Varraso, F Barbano, A Capotorto, F Dicembrino, F Petruzzelli, G Rubini |
Journal | Anticancer research
(Anticancer Res)
1999 Nov-Dec
Vol. 19
Issue 6C
Pg. 5587-91
ISSN: 0250-7005 [Print] Greece |
PMID | 10697623
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Antineoplastic Agents
- Antineoplastic Agents, Phytogenic
- Chelating Agents
- Chromium Radioisotopes
- Edetic Acid
- Carboplatin
- Paclitaxel
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Agents, Phytogenic
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(therapeutic use)
- Chelating Agents
(pharmacokinetics)
- Chromium Radioisotopes
- Edetic Acid
(pharmacokinetics)
- Female
- Glomerular Filtration Rate
- Humans
- Metabolic Clearance Rate
- Middle Aged
- Ovarian Neoplasms
(drug therapy, metabolism)
- Paclitaxel
(therapeutic use)
|